News and Trends 5 Sep 2017 UPDATE: Austrian Biotech receives €3.3M boost for its Chikungunya Vaccine UPDATE (05/09/2017): Innovate UK has granted Themis £3M (€3.3M) to push its Chikungunya Vaccine towards Phase III. Originally Published 06/06/2017 Themis Bioscience will test its vaccine candidate against Chikungunya fever… September 5, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
Startup Scout 13 Sep 2023 PIM kinase inhibition: a Swiss startup’s unique approach to tackling complex autoimmune disorders …be used to confirm a PIM kinase inhibitor clinical candidate for development within nine to 12 months. According to the company, a lead has already been identified, and is currently… September 13, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
More News! 27 Jun 2019 German Biotech Will Target Parkinsonian Disorders with €12M Series A Modag has developed a candidate drug targeting the neurodegenerative disease multiple system atrophy, which it plans to take to the clinic with €12M in Series A funds. Multiple system atrophy… June 27, 2019 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Sponsored by Lonza 9 Sep 2025 Advanced expression vector design to overcome challenges in developing multichain biotherapeutics …monoclonal antibodies, which have identical heavy chains (HCs) and light chains (LCs), multichain biotherapeutics can have three or four unique antibody or antibody-like polypeptide chains, so it is important to… September 9, 2025 - 8 minutesmins - By Jennifer Tsang Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jan 2023 BioInvent receives funding for blood cancer treatments …antibody BI-1206, in non-Hodgkin’s lymphoma (NHL) and the anti-TNFR2 antibody BI-1808 in cutaneous T-cell lymphoma (CTCL). “We are delighted to conclude this agreement with the widely respected patient organization Leukemia… January 18, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2017 Novartis Scores Major Phase III Win with New Cardiovascular Drug …in one of the largest and longest-running Phase III trials in the company’s history. Canakinumab is a fully human monoclonal antibody that inhibits IL-1ß, a key cytokine in the inflammatory… June 22, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
Best in Biotech 4 Nov 2019 Top 10 Biotech Companies Leaving a Mark in Munich …biotech industry. MorphoSys Morphosys is one of just a few biotech companies in Europe valued at over €1Bn. Founded in 1992, the company specializes in the development of antibody treatments… November 4, 2019 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2016 UPDATE: FDA rejects Sanofi’s promising Rheumatoid Arthritis Drug …improvement in physical function of patient joints. There is a strong competition for antibody research into chronic auto-immune diseases such as Rheumatoid. A few Biotech giants are extra anxious to… October 31, 2016 - 3 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
In Depth 2 Jan 2018 The Labiotech Dictionary of Important Biotech Terms …up to the immune system for destruction. The structure of an antibody, which allows it to bind dangerous pathogens, fight infection and stimulate an immune response. Some of Europe’s best… January 2, 2018 - 14 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 16 Sep 2022 Marengo advancing its lead TCR activator into clinic after FDA clearance …a bi-functional fusion antibody that deploys a mechanism of T cell activation that has demonstrated potent single agent activity in PD-1 refractory settings in preclinical studies. Marengo Therapeutics plans to… September 16, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 6 Aug 2019 ADC Therapeutics and SOPHiA Genetics Team Up to Personalize Cancer Treatment …who will respond best to the drug. No financial details of the deal were disclosed. ADC Therapeutics’ drug is an antibody that is chemically joined to a molecule that kills… August 6, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jan 2023 EMA accepts Marketing Authorization Application for lecanemab to treat early Alzheimer’s disease …beta (Aβ) protofibril antibody, for the treatment of early Alzheimer’s disease (mild cognitive impairment due to Alzheimer’s disease (AD) and mild AD dementia) with confirmed amyloid pathology, for review following… January 27, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email